Asapiprant: meta-analysis of COVID-19 studies

All studies Mortality ICU Serious outcomes RCTs RCT mortality All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−63%

Mortality (1)−63%

ICU admission (1)−32%

RCTs (1)−63%

Late (1)−63%

00.511.5+

← Asapiprant
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Asapiprant COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.42death16/9610/98

Late treatment−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.4216/9610/98

Late treatment−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Wilkerson (DB RCT)−32%1.32 · 0.75–2.3322/9617/98

Late treatment−32%1.32 · 0.75–2.3322/9617/9832% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.34

All studies−32%1.32 · 0.75–2.3322/9617/9832% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.3400.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.42death16/9610/98

Late treatment−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.42death16/9610/98

Late treatment−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.4216/9610/98

Late treatment−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.19

All studies−63%1.63 · 0.78–3.4216/9610/9863% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.1900.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →

c19early.org

October 2026

Asapiprant COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wilkerson (DB RCT)−63%1.63 · 0.78–3.42death16/9610/98 Wilkerson (DB RCT)−32%1.32 · 0.75–2.33ICU22/9617/98 Wilkerson (DB RCT)−24%1.24 · 0.82–1.87severe case34/9628/98 Wilkerson (DB RCT)−33%1.33 · 0.89–2.00no improv.96 (n)98 (n) Wilkerson (DB RCT)−23%1.23 · 0.79–1.91progression31/9426/97

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Asapiprant
reduces riskAsapiprant
increases risk →